Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.59 |
| ▸ | MPL | P40238 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | USP8 | P40818 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727086 | 0.89 | NPSR1 (0.59) | KDM1AMPLMEN1KMT2ANPSR1 | |
| SCHEMBL16798990 | 0.89 | MEN1 (0.66) | KDM1AMPLMEN1KMT2AUSP2 | |
| SCHEMBL8357471 | 0.87 | MEN1 (0.63) | KDM1AMPLMEN1KMT2APOLB | |
| SCHEMBL8110979 | 0.84 | KDM1A (0.61) | KDM1AMPLMEN1KMT2ANPSR1 | |
| SCHEMBL8360832 | 0.84 | MAPT (0.64) | KDM1AMPLMEN1KMT2AUSP2 | |
| SCHEMBL8355149 | 0.83 | MEN1 (0.54) | KDM1AMPLMEN1KMT2ASCN9A | |
| SCHEMBL474303 | 0.75 | MPL (1.00) | KDM1AMPLMEN1KMT2A | |
| SCHEMBL23611061 | 0.74 | KDM1A (0.78) | KDM1AMEN1KMT2ANPSR1USP2 | |
| Bromide SCHEMBL8359366 | 0.74 | MPL (0.97) | KDM1AMPLMEN1KMT2A | |
| SCHEMBL712653 | 0.73 | SCN9A (0.61) | MPLSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4813800-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | claimed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | claimed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | claimed |
| US-7727977-B2 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | KYNU, KMO, IDO1 | KDM1A 190/4885MPL 3355/4885MEN1 2965/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | KDM1A 368/4885MPL 3917/4885MEN1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.